Related Experiment Video
Updated: Jan 27, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Skeletal-Related Events in Patients With Multiple Myeloma and Prostate Cancer Who Receive Standard vs
Abigail Shell1, Leigh Anne Keough1, Kothanur Rajanna1
1is a Pharmacist at the Piedmont Atlanta Hospital in Georgia. and are Clinical Pharmacy Specialists in the Department of Hematology/Oncology at the Memphis VAMC in Tennessee.
Abstract:
In patients with multiple myeloma and prostate cancer, extending the bisphosphonate dosing interval may help decrease medication-related morbidity without compromising therapeutic benefit.
More Related Videos
Related Concept Videos
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
Drug Dosing: Geriatric Patients
Drug Dosing: Obese Patients
Bioavailability Study Design: Single Versus Multiple Dose Studies
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

